PT  - JOURNAL ARTICLE
AU  - Takao Fujii
AU  - Masashi Akizuki
AU  - Hideto Kameda
AU  - Mami Matsumura
AU  - Michito Hirakata
AU  - Tadashi Yoshida
AU  - Taeko Shinozawa
AU  - Tsuneyo Mimori
TI  - Methotrexate treatment in patients with adult onset Still’s disease—retrospective study of 13 Japanese cases
AID  - 10.1136/ard.56.2.144
DP  - 1997 Feb 01
TA  - Annals of the Rheumatic Diseases
PG  - 144--148
VI  - 56
IP  - 2
4099  - http://ard.bmj.com/content/56/2/144.short
4100  - http://ard.bmj.com/content/56/2/144.full
SO  - Ann Rheum Dis1997 Feb 01; 56
AB  - OBJECTIVE To evaluate methotrexate treatment in patients with active adult onset Still’s disease (AOSD).METHODS Methotrexate was initially given as a single weekly oral dose of 5 mg and adjusted individually afterwards in 13 patients with active AOSD. Symptoms and laboratory findings were investigated.RESULTS Signs of AOSD activity disappeared (remission) in eight patients between 3 and 16 weeks after starting methotrexate. In these patients, significant improvements in C reactive protein, erythrocyte sedimentation rate, white blood count, and serum ferritin were observed at 8, 12, 14, and 16 weeks after starting methotrexate, respectively. In six of these eight patients, steroids or non-steroidal anti-inflammatory drugs could be reduced or discontinued. In four patients methotrexate was not effective despite 12 or 16 weeks of treatment, and one patient discontinued treatment after 2 weeks because of severe nausea. Five patients suffered from adverse reactions, including acute interstitial pneumonia (one patient) and liver toxicity (two patients). Five out of eight patients successfully treated with methotrexate were HLA-DR4 positive (four homozygotes), and all the unsuccessfully treated patients were DR2 positive.CONCLUSIONS Methotrexate is useful for controlling disease activity in AOSD, not only for refractory patients but also for patients who have never taken steroids or for those with steroid associated toxicity. However, serious adverse reactions can occur, as with rheumatoid arthritis. It is important to determine the critical factors, such as the immunogenetic background, that are associated with response to methotrexate treatment.